NCT06828120View on ClinicalTrials.gov

A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

September 3, 2025

Study Completion Date

September 17, 2025

Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
DRUG

Taneasy 600mg granules

Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.

DRUG

Fluimucil 600mg granules

Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.

Trial Locations (1)

Unknown

Taipei Veterans General Hospital, Taipei

Sponsors
All Listed Sponsors
collaborator

Clinny biotech limited

UNKNOWN

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

lead

Bun Yao Biotechnology Co., Ltd

INDUSTRY

NCT06828120 - A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects | Biotech Hunter | Biotech Hunter